New Data For Presentation At ASCO 2008
LONDON and PHILADELPHIA, April 22 /PRNewswire/ -- GlaxoSmithKline Oncology will present a wide range of new data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago starting Friday, May 30th. The data cover a variety of therapies, experimental medicines and immunotherapeutics for the treatment and supportive care of cancer patients. At this year's ASCO meeting, GSK Oncology will present data that demonstrate trends in cancer research, including the combination of targeted therapies and a focus on oral treatment options.
GSK will make data presentations for TYKERB(R) (lapatinib), which is approved in more than 20 countries, including the US. The US indication is in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
New data will also be presented for HYCAMTIN(R) (topetecan HCl). GSK will also present data for several investigational medicines, including the oral multikinase angiogenesis inhibitor, ARMALA(TM) (pazopanib); the neurokinin-1 receptor antagonist, REZONIC(TM) (casopitant); the oxidative stress inducer, elesclomol and the antigen-specific cancer immunotherapeutic, MAGE-A3 ASCI.
Highlights of the GSK Oncology data to be presented at ASCO include:
A randomized study of lapatinib (TYKERB) in combination with trastuzumab vs. lapatinib monotherapy in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [Phase III]Dr. Joyce O'Shaughnessy, Baylor-Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas, TX, abstract # 1015, oral presentation, Sunday, June 01, 2008, 9:15 am - 9:30 am, E-Hall D1
Randomized study of pazopanib + lapatinib vs. lapatinib alone in
patients with HER2+ advanced or metastatic brea
Copyright©2008 PR Newswire.
All rights reserved